The estimated Net Worth of Dinah Ph.D. Sah is at least $969 Tisíc dollars as of 27 February 2018. Dinah Sah owns over 15,623 units of Voyager Therapeutics Inc stock worth over $969,073 and over the last 7 years Dinah sold VYGR stock worth over $0.
Dinah has made over 1 trades of the Voyager Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Dinah exercised 15,623 units of VYGR stock worth $155,918 on 27 February 2018.
The largest trade Dinah's ever made was exercising 15,623 units of Voyager Therapeutics Inc stock on 27 February 2018 worth over $155,918. On average, Dinah trades about 5,208 units every 0 days since 2018. As of 27 February 2018 Dinah still owns at least 154,311 units of Voyager Therapeutics Inc stock.
You can see the complete history of Dinah Sah stock trades at the bottom of the page.
Dinah's mailing address filed with the SEC is 75 Sidney St, Cambridge, MA 02139, USA.
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 a Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include: